Feed Top Reports Pricing

⌘K

17:34:58·24d

SECFiling

SEC Form 10-K filed by Genprex Inc.

GNPX· Genprex Inc.

Health Care

Full content unavailable. See the original source below.

Original source

Companies

GNPX
Genprex Inc.
Health Care

Related

PR2d
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
SEC3d
Genprex Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
PR3d
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
PR4d
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
SEC6d
SEC Form PRE 14A filed by Genprex Inc.
INSIDER8d
SEC Form 4 filed by Longnecker Brent M
SEC37d
Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
PR37d
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022